BONE METABOLIC DETERMINANTS OF THE EFFICACY OF ZOMETA IN PATIENTS WITH DISSEMINATED PROSTATE CANCER
https://doi.org/10.17650/1726-9776-2009-5-3-48-52
Abstract
The efficacy of Zometa has been evaluated in the treatment of patients with disseminated prostate cancer. The use of Zometa as an inhibitor of bone resorption in the presence moderate changes in the activity of bone resorptive processes has shown the highest survival rates.
About the Authors
Yu. G. Alyaev
Clinic of Urology, I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
A. Z. Vinarov
Clinic of Urology, I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
V. M. Shelepova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
Yu. L. Demidko
Clinic of Urology, I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
References
1. Оха У.К., Логью Дж. Рак простаты. М.: Рид Элсивер, 2009.
2. Мазо Е.Б., Григорьев М.Э., Конорев В.А. Диагностическая и прогностическая ценность маркеров костного метаболизма в мониторинге больных раком предстательной железы, получающих гормональную терапию. В сб.: Материалы 2-го Конгресса РООУ. М., 2007.
3. Беневоленская Л.И. Бисфосфонаты и остеопороз. В кн.: Руководство по остеопорозу. Под ред. Л.И. Беневоленской. М.: БИНОМ. Лаборатория знаний, 2003.
4. Russell R.G., Croucher P.I., Rogers M.J. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9(Suppl 2): 66—80.
5. Кушлинский Н.Е., Любимова Н.В. Бисфосфонаты в лечении метастазов рака предстательной железы в кости. В кн.: Рак предстательной железы. Под ред. Н.Е. Кушлинского, Ю.Н. Соловьева, М.Ф. Трапезниковой. М.: РАМН, 2002.
6. Body J.J., Lortholary A., Romieu G. et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14(9):1557—61.
7. Lipton A., Theriault R.L., Hortobagyi G.N. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88(5):1082—90.
8. Migliorati C.A., Siegel M.A., Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7(6):508—14.
9. Матвеев Б.П., Карякин О.Б., Матвеев В.Б. и др. Зомета в лечении больных распространенным раком предстательной железы (результаты Российского многоцентрового исследования). Совр онкол 2004;6(3).
10. Hillner B.E., Ingle J.N., Chlebowski R.T. et al. Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21(21):4042—57.
11. Brown J.E., Cook R.J., Major P. et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97(1): 59—69.
12. Kyle R.A. Yee G.C., Somerfield M.R. et al. Clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25(17): 2464—72.
13. Герасимов А.Н. Медицинская статистика. М.: МИА, 2007.
Review
For citations:
Alyaev Yu.G., Vinarov A.Z., Shelepova V.M., Demidko Yu.L. BONE METABOLIC DETERMINANTS OF THE EFFICACY OF ZOMETA IN PATIENTS WITH DISSEMINATED PROSTATE CANCER. Cancer Urology. 2009;5(3):48-52. (In Russ.) https://doi.org/10.17650/1726-9776-2009-5-3-48-52
Views:
677
Email this article 